Amneal Pharmaceuticals, Inc.AMRXEarnings & Financial Report
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Revenue
$695.4M
Gross Profit
$255.9M
Operating Profit
$100.3M
Net Profit
$12.2M
Gross Margin
36.8%
Operating Margin
14.4%
Net Margin
1.8%
YoY Growth
5.5%
EPS
$0.04
Amneal Pharmaceuticals, Inc. Q1 FY2025 Financial Summary
Amneal Pharmaceuticals, Inc. reported revenue of $695.4M (up 5.5% YoY) for Q1 FY2025, with a net profit of $12.2M (up 113.3% YoY) (1.8% margin). Cost of goods sold was $439.5M, operating expenses totaled $155.5M.
Key Financial Metrics
| Total Revenue | $695.4M |
|---|---|
| Net Profit | $12.2M |
| Gross Margin | 36.8% |
| Operating Margin | 14.4% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Amneal Pharmaceuticals, Inc. Q1 FY2025 revenue of $695.4M breaks down across 13 segments, led by Oral Solid at $179.0M (25.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Oral Solid | $179.0M | 25.7% |
| Distribution Service | $104.9M | 15.1% |
| Central Nervous System | $67.6M | 9.7% |
| Other Dosage Forms | $56.4M | 8.1% |
| Government Label | $50.1M | 7.2% |
| Ephinephrine Auto Injector | $48.2M | 6.9% |
| Transdermal | $43.1M | 6.2% |
| Injectable | $34.8M | 5.0% |
| Hormonal Allergy | $34.2M | 4.9% |
| Biosimilar | $28.5M | 4.1% |
| Oral Liquid | $23.5M | 3.4% |
| Selling General And Administrative Expenses | $10.8M | 1.6% |
| Other Therapeutic Classes | $6.5M | 0.9% |
Amneal Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Amneal Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Oral Solid and Distribution Service) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Oral Solid | — | $188.7M | $180.5M | $178.3M |
| Distribution Service | — | $107.7M | $96.2M | $99.7M |
| Central Nervous System | — | $104.8M | $77.6M | $83.4M |
| Other Dosage Forms | — | $68.2M | $59.7M | — |
| Government Label | — | $86.8M | $87.8M | $45.4M |
Amneal Pharmaceuticals, Inc. Annual Revenue by Year
Amneal Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.0B).
| Year | Annual Revenue |
|---|---|
| 2025 | $3.0B |
| 2024 | $2.8B |
| 2023 | $2.4B |
| 2022 | $2.2B |
Amneal Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Amneal Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $722.5M | +3.9% | $78.0M | 10.8% |
| Q4 FY2025 | $814.3M | +11.5% | $35.1M | 4.3% |
| Q3 FY2025 | $784.5M | +11.7% | $2.4M | 0.3% |
| Q2 FY2025 | $724.5M | +3.2% | $22.4M | 3.1% |
| Q1 FY2025 | $695.4M | +5.5% | $12.2M | 1.8% |
| Q4 FY2024 | $730.5M | +18.4% | $-31.1M | -4.3% |
| Q3 FY2024 | $702.5M | +13.3% | $-156.0K | -0.0% |
| Q2 FY2024 | $701.8M | +17.1% | $6.0M | 0.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $701.8M | $702.5M | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M |
| YoY Growth | 17.1% | 13.3% | 18.4% | 5.5% | 3.2% | 11.7% | 11.5% | 3.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.51B | $3.46B | $3.50B | $3.37B | $3.42B | $3.60B | $3.68B | $3.54B |
| Liabilities | $3.57B | $3.55B | $3.61B | $3.50B | $3.53B | $3.71B | $3.75B | N/A |
| Equity | $-57.5M | $-93.4M | $-109.3M | $-131.7M | $-112.1M | $-109.5M | $-70.8M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $39.7M | $141.8M | $118.1M | $7.4M | $83.8M | $118.5M | $130.3M |